This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Precision Medicine Conference" (IPMC 2023) scheduled during April 24-26, 2023 in Orlando, Florida, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at firstname.lastname@example.org or call + 1 (702) 988 2320.
Precision medicine is radically altering the generation of therapies. Its personalized, focused approach to health care has a broad impact on everything from genomics to medical devices, and as a result, it is spawning new revenue models for companies across the industry. Precision medicine's crucial benefits are being brought to market due to recent breakthroughs. These include the ability to enhance chronic disease patient outcomes, an improvement in product pipeline and speed-to-market for life sciences companies, and the ability to quickly remove research paths that are unlikely to succeed. The transition toward a greater understanding of disease based on molecular biology will inevitably result in a new, more precise disease categorization, which will include new molecular understanding to establish a new taxonomy.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Leveraging blockchain technology, edge computing and federated learning to enhance outcomes in precision medicine
Ingrid Vasiliu Feltes, MEDNAX, United States
Title : The new horizons in the patient- centered care for understanding of the reasons of its health problems – Psychosynthesis approach
Ewa Danuta Bialek, Institute of Psychosynthesis, Poland
Title : Hegazy theory for interpretation of human parthenogenesis: A new hypothesis
Abdelmonem Awad Hegazy, Zagazig University, Egypt
Title : Precision Oncology and Personalised Medicine: Innovative Technology for the Treatment of Colorectal Cancer
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : The role of CD44v6 as a new immunotherapy target for urothelial cancer
Iris Adriana Maria Lodewijk, Institute of Biomedical Research, Spain